Vazyme is ready to enter the Middle East market and showcases its COVID-19 testing solutions at Medlab Middle East 2022 | Messages

0

DUBAIUnited Arab Emirates, January 28, 2022 /PRNewswire/ — Leading China-based biotech company Vazyme (688105.SH) attended the 2022 edition of Medlab Middle East at Dubai World Trade Center (DWTC). January 24thth until 27th, a premier laboratory and flagship exhibition and conference that brings together global medical communities to showcase the best in laboratory innovations and technologies. At booth #Z5.H20, the company showcased its complete product portfolio for COVID-19 testing solutions as well as advanced IVD products for online and in-person event attendees. Most of the more than 500 visitors came out middle East region and the rest originated from India, Turkeyetc. The most popular product on display was the COVID-19 Antigen Rapid Self-Test Kit, which provides test results in 10 minutes and achieves an accuracy of 99.81%.

“As the Omicron variant begins to gain traction, hospitals and testing centers are struggling, underscoring the need to scale up production of rapid and reliable COVID-19 test kits to track a new wave of infections. We want to help the medical communities in the middle East and Africa to address this issue by showcasing our high quality COVID-19 testing products and solutions at Medlab 2022 as part of our efforts to strengthen local response to the pandemic,” said by jenny Jiang, International Business Manager of Vazyme.

The event featured Vazyme’s full range of nucleic acid detection solutions, along with other products for COVID-19 detection, including a range of antigen detection kits, COVID-19 vaccine antibody evaluation solutions and detection solution raw material products. One of the highlights of its exhibition, Vazyme Automatic Nucleic Acids Extraction System, has received marketing approvals from the United Arab Emirates and UAE governments Saudi Arabiaand its 2019-nCoV Triplex RT-qPCR Detection Kit was also recently approved for UAE market entry.

Ten years into its existence, Vazyme has consolidated its leadership position of China Biotech industry with sufficient production capacity of IVD production line, equivalent to 1 million units per day. Vazyme’s MENA-based team consists of IVD product experts who provide comprehensive services and individualized installment advice to local consumers. Vazyme has fueled its global expansion in 2021 by establishing its first wholly owned overseas subsidiary Indonesiawith offices and warehouses in the US, EU and Hong Kong SAR Serving and supporting customers worldwide.

“We’re celebrating the 10thth anniversary of our company since it was founded this year. As a pioneer in advancing innovation in life sciences, Vazyme’s mission is to use science and technology to improve health and life, addressing the world’s unmet medical needs while maintaining the highest standards of ethics, accountability and professionalism to comply with Our R&D-centric approach allows us to constantly innovate and bring new products and solutions to our customers. We will continue to work with our partners around the world and build on our past efforts to strengthen medical capabilities in the fight against serious diseases,” said by jenny Jiang.

View original content to download multimedia: https://www.prnewswire.com/news-releases/ready-to-enter-the-middle-east-market-vazyme-showcases-its-covid-19-testing -solutions-at-medlab-near-east-2022-301469566.html

SOURCE Vazyme

Share.

Comments are closed.